新型基于阿克里丁的LSD1抑制剂增强了胃癌的免疫反应
Xing-Jie Dai1, Ying Liu2, Ning Wang3
1Key Laboratory of Advanced Drug Preparation Technologies, Ministry of Education, China; State Key Laboratory of Esophageal Cancer Prevention & Treatment, Key Laboratory of Henan Province for Drug Quality and Evaluation, Institute of Drug Discovery and Development, School of Pharmaceutical Sciences, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, 450001, Henan Province, China.
一种新的化合物,5ac,在胃癌中有效抑制了基因组 lysine 特定去甲基酶 1 (LSD1). 这种新型抑制剂增强了免疫反应,抑制了瘤生长,显示了癌症免疫治疗的前景.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药用化学 医学化学
背景情况:
- 素基因特异性去甲基酶1 (LSD1) 是癌症免疫治疗的有希望的标.
- 之前的研究已经确定了LSD1抑制剂DXJ-1.
研究的目的:
- 开发基于DXJ-1结构的新型,强效的LSD1抑制剂.
- 在胃癌模型中评估这些抑制剂的疗效.
主要方法:
- 基于结构的药物设计和合成基于阿克里丁的化合物.
- 在体外酶抑制试验和分子对接.
- 在胃癌细胞系 (BGC-823,MFC) 的体外研究和体内小鼠模型.
主要成果:
- 化合物5ac表现出显著增强的LSD1抑制活性 (IC50 = 13nM),比DXJ-1强4.6倍.
- 分子对接证实了5ac与LSD1活性部位的结合.
- 5ac抑制了胃癌细胞的干细胞和迁移,减少了PD-L1的表达,并增加了T细胞介导的杀死.
- 在小鼠中,5ac抑制了瘤生长.
结论:
- 化合物5ac是一种强大的LSD1抑制剂,有可能增强胃癌的免疫反应.
- 5ac通过准LSD1和调节瘤微环境,证明了胃癌治疗的治疗潜力.
更多相关视频
15:24Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
